Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Respiratory system agents

NHS Scotland to provide £100,000-per-year cystic fibrosis drug

A five-year deal to supply NHS Scotland with cystic fibrosis (CF) drugs Orkambi and Symkevi has been secured after discussions between the manufacturer, Vertex Pharmaceuticals, and the Scottish government.

The agreement, announced on 12 September 2019, means that the medicines will now be made available to patients on the NHS in Scotland, “subject to a confidential discount”, said Jeane Freeman, the Scottish health secretary.

The Scottish Medicines Consortium and the National Institute for Health and Care Excellence (NICE) in England have both ruled that these medicines do not provide sufficient value for money. Announcing its decision in June 2016, NICE said it would cost £104,000 per patient per year to provide Orkambi to CF patients.

NHS England has since held discussions with Vertex about obtaining Orkambi and other CF drugs at a cheaper price. However, in a statement published after the Scottish government announcement, NHS England said Vertex had “rejected the health service’s offer”, which was “the largest offer the NHS has ever made for a treatment of its kind”.

“The NHS cannot offer a blank cheque to an individual company at the expense of our ability to provide a wide range of treatments to as many people as possible,” it added.

The Scottish government estimates that 350 eligible people living in Scotland will have access to the drugs, which can stabilise their lung health and reduce the need for hospital admissions.

NHS England said the NHS “continues to look at, and design, viable alternative solutions to bringing treatments to [people living with] cystic fibrosis”.

David Ramsden, chief executive of the Cystic Fibrosis Trust, described the Scottish deal as a “landmark moment” for people with CF and their families.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20207064

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Sport and Exercise Medicine for Pharmacists

    Sport and Exercise Medicine for Pharmacists

    All the information you need to provide patients with evidence-based advice on sports and exercise related health matters.

    £27.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.